NO-aspirins: a class of new anti-inflammatory and antithrombotic agents
- PMID: 10431210
- DOI: 10.1016/s0165-6147(99)01353-x
NO-aspirins: a class of new anti-inflammatory and antithrombotic agents
Similar articles
-
Focused antithrombotic therapy: novel anti-platelet salicylates with reduced ulcerogenic potential and higher first-pass detoxification than aspirin in rats.J Lab Clin Med. 1998 Dec;132(6):469-77. doi: 10.1016/s0022-2143(98)90124-x. J Lab Clin Med. 1998. PMID: 9851736
-
Dual COX-inhibitors: the answer is NO?Curr Top Med Chem. 2005;5(5):487-92. doi: 10.2174/1568026054201677. Curr Top Med Chem. 2005. PMID: 15974943 Review.
-
[Pharmacology of NSAIDS].Internist (Berl). 2000 Jan;41(1):66. Internist (Berl). 2000. PMID: 10712092 German. No abstract available.
-
[Pharmacology of aspirin].Rev Med Interne. 2000 Mar;21 Suppl 1:18s-26s. doi: 10.1016/s0248-8663(00)88721-4. Rev Med Interne. 2000. PMID: 10763201 Review. French.
-
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G76-81. doi: 10.1152/ajpgi.00295.2003. Am J Physiol Gastrointest Liver Physiol. 2004. PMID: 14665439
Cited by
-
A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin.Br J Pharmacol. 2000 Jan;129(2):343-50. doi: 10.1038/sj.bjp.0703064. Br J Pharmacol. 2000. PMID: 10694241 Free PMC article.
-
Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential.Medchemcomm. 2013;4(11):10.1039/C3MD00185G. doi: 10.1039/C3MD00185G. Medchemcomm. 2013. PMID: 24273639 Free PMC article.
-
GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway.Mol Cancer Res. 2011 Feb;9(2):195-202. doi: 10.1158/1541-7786.MCR-10-0363. Epub 2010 Dec 14. Mol Cancer Res. 2011. PMID: 21156786 Free PMC article.
-
Nitric Oxide-Releasing Hybrid Drugs Target Cellular Processes Through S-Nitrosylation.For Immunopathol Dis Therap. 2012;3(2):97-108. doi: 10.1615/ForumImmunDisTher.2012006099. For Immunopathol Dis Therap. 2012. PMID: 23730526 Free PMC article.
-
Nitric oxide modulators: an emerging class of medicinal agents.Indian J Pharm Sci. 2012 Nov;74(6):487-97. doi: 10.4103/0250-474X.110572. Indian J Pharm Sci. 2012. PMID: 23798773 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources